Oncolytics Biotech, Inc. (USA) (OTCMKTS:ONCYF) announced that enrollment has commenced in a Phase Ib study of REOLYSIN® combined with standard doses of bortezomib (Kyprolis®) …
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that it has received notification from OTC Markets Group Inc.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that, following submission to the U.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that Dr.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced the encore presentation of findings from a post-hoc analysis examining the effects of icosapent ethyl (Vascepa®) on Apolipoprotein …
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that enrollment has been completed in a randomized Phase II study of REOLYSIN® in patients with previously treated advanced …
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced the voting results from its Annual Meeting of Shareholders held on Monday June 8th, 2015.
Canaccord Genuity analyst Neil Maruoka came out with his views on Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), after the company provided updated guidance on its planned registration …
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that it has received a letter from the NASDAQ OMX Group (“Nasdaq”) determining that the Company is …